Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Abraham

Showing results (811-820 of 826) with videos related to

Pageof 83
Sort By:
Lancet (London, England)|September 2, 2020
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, et al.
Journal for Immunotherapy of Cancer|January 11, 2024
<i>CCR5</i> and <i>CCL5</i> gene expression in colorectal cancer: comprehensive profiling and clinical valueFrancesca Battaglin, Yasmine Baca, Joshua Millstein, et al.
Oncogene|November 3, 2021
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancerHiroyuki Arai, Andrew Elliott, Joshua Millstein, et al.
JACC. Heart Failure|November 30, 2023
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study DesignCaroline J Coats, Martin S Maron, Theodore P Abraham, et al.
Journal of Cardiac Failure|March 17, 2024
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Ahmad Masri, Mark V Sherrid, Theodore P Abraham, et al.
Circulation. Cardiovascular Imaging|January 12, 2019
Interobserver Variability in Applying American Society of Echocardiography/European Association of Cardiovascular Imaging 2016 Guidelines for Estimation of Left Ventricular Filling PressureSherif F Nagueh, Theodore P Abraham, Gerard P Aurigemma, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|July 5, 2015
A Summary of the American Society of Echocardiography Foundation Value-Based Healthcare: Summit 2014: The Role of Cardiovascular Ultrasound in the New ParadigmBenjamin F Byrd, Theodore P Abraham, Denis B Buxton, et al.
The New England Journal of Medicine|May 13, 2024
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.
Journal of the American College of Cardiology|October 1, 2024
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Pageof 83

Showing results (811-820 of 826) with videos related to

Sort By:
Pageof 83
Lancet (London, England)|September 2, 2020
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, et al.
Journal for Immunotherapy of Cancer|January 11, 2024
<i>CCR5</i> and <i>CCL5</i> gene expression in colorectal cancer: comprehensive profiling and clinical valueFrancesca Battaglin, Yasmine Baca, Joshua Millstein, et al.
Oncogene|November 3, 2021
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancerHiroyuki Arai, Andrew Elliott, Joshua Millstein, et al.
JACC. Heart Failure|November 30, 2023
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study DesignCaroline J Coats, Martin S Maron, Theodore P Abraham, et al.
Journal of Cardiac Failure|March 17, 2024
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Ahmad Masri, Mark V Sherrid, Theodore P Abraham, et al.
Circulation. Cardiovascular Imaging|January 12, 2019
Interobserver Variability in Applying American Society of Echocardiography/European Association of Cardiovascular Imaging 2016 Guidelines for Estimation of Left Ventricular Filling PressureSherif F Nagueh, Theodore P Abraham, Gerard P Aurigemma, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|July 5, 2015
A Summary of the American Society of Echocardiography Foundation Value-Based Healthcare: Summit 2014: The Role of Cardiovascular Ultrasound in the New ParadigmBenjamin F Byrd, Theodore P Abraham, Denis B Buxton, et al.
The New England Journal of Medicine|May 13, 2024
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.
Journal of the American College of Cardiology|October 1, 2024
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Pageof 83